Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $38.19 USD
Change Today 0.00 / 0.00%
Volume 0.0
OCPNF On Other Exchanges
Symbol
Exchange
Tokyo
OTC US
OTC US
Frankfurt
As of 8:10 PM 03/25/15 All times are local (Market data is delayed by at least 15 minutes).

olympus corp (OCPNF) Snapshot

Open
$38.19
Previous Close
$38.19
Day High
$38.19
Day Low
$38.19
52 Week High
03/25/15 - $38.19
52 Week Low
05/5/14 - $30.85
Market Cap
13.1B
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
342.7M
EX-Date
03/27/14
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for OLYMPUS CORP (OCPNF)

Related News

No related news articles were found.

olympus corp (OCPNF) Related Businessweek News

View More BusinessWeek News

olympus corp (OCPNF) Details

Olympus Corporation manufactures and sells precision machineries and instruments worldwide. It operates in four segments: Medical Business, Scientific Solutions Business, Imaging Business, and Others Business. The Medical Business segment provides endoscopy systems comprising videoscopes, video processors, light sources, and liquid crystal display panels; peripheral equipment, such as image recording devices, endoscope cleaning systems, sterilization systems, etc.; surgical video endoscopy systems, peripheral devices for endoscopic surgery, electrosurgical knives, etc.; and endoscopic devices for various diagnostic and treatment procedures, including biopsy forceps, high-frequency polypectomy snares, grasping forceps, stone retrieval and lithotriptor baskets, hemostasis accessories, etc. The Scientific Solutions Business segment offers upright and polarizing microscopes, inverted microscopes, laser confocal microscopes, box-type fluorescence imaging devices, stereo microscopes, fluorescence macro microscopes, microscope digital cameras, imaging software, bio-imaging systems, and virtual slide systems; and metallurgical microscopes, semiconductor inspection microscopes, laser and measuring microscopes, microscopic 3D measurement systems, industrial videoscopes and fiberscopes, industrial rigid scopes, ultrasonic flaw detectors, eddy current flaw detectors, phased array flaw detectors, X-ray diffraction analyzers, and peripheral equipment. The Imaging Business segment offers digital single-lens cameras, compact digital cameras and related products, digital camera lens barrels, and optical components, as well as IC recorders and binoculars. The Others Business segment manufactures biomedical materials, as well as conducts system development and other business activities. The company was formerly known as Olympus Optical Co., Ltd. and changed its name to Olympus Corporation in October 2003. Olympus Corporation was founded in 1919 and is headquartered in Tokyo, Japan.

30,702 Employees
Last Reported Date: 06/26/14
Founded in 1919

olympus corp (OCPNF) Top Compensated Officers

President and Representative Director
Total Annual Compensation: ¥100.0M
Compensation as of Fiscal Year 2014.

olympus corp (OCPNF) Key Developments

Terumo Corporation Concludes Basic Agreement with Olympus Corporation to Expand Business Partnership Covering Medical Interventional System Products in the United States

Terumo Corporation announced that it has concluded a basic agreement with Olympus Corporation to expand their business partnership covering medical interventional system products in the United States. With this move, both companies will, for the first time, jointly market products in the field of Urology in the U.S., as well as explore opportunities to broaden the types of products offered in the field of Gastroenterology, which is already an established area of focus of the partnership. The objective of the expanded partnership is to achieve business growth in the U.S., by leveraging the competitive advantages of both companies. The partnership joins the guidewire brand with the endoscope brand. Olympus and Terumo have jointly developed a guidewire since 2009, which is designed for guiding minimally invasive treatment devices during biliary endoscopy procedures. Through the partnership, Terumo will benefit from the U.S. presence and marketing arm of Olympus in the Urology and Gastroenterology spaces, and Olympus will broaden its assortment of guidewires from Terumo. Terumo’s guidewire has gained widespread endorsements in the U.S. as a diagnostic and intravascular treatment tool. The research and development efforts through the partnership will be aligned toward improving quality of care and advancing minimally invasive procedures. Guidewires produced by Terumo will be supplied by Terumo’s U.S. subsidiary, Terumo Medical Corporation, for Olympus’s U.S. subsidiary, Olympus America Inc. Plans are in place for Olympus America Inc. to distribute—to the US market—Terumo’s urologic products beginning this May and biliary products later in 2015. Terumo also intends to continue separately marketing its interventional system products in the fields of cardiology, peripheral artery disease, and neurovascular disease in the United States.

Olympus Corporation Releases New Biological Microscope

Olympus Corporation has announced that its scientific solutions business has released biological microscope CX23. Olympus supplies an extensive range of biological microscopes that extend from its top-end FLUOVIEW series of microscopes used in the latest life science research through to its workhorse BX3/IX3 series and the CX series of entry-level models used for laboratory teaching in universities and other educational institutions. It is contributing to the progress of life science by offering products that meet a diverse range of needs. The new CX23 is the successor to the existing CX22LED entry-level model and represents the first model change in four years. While maintaining Olympus's tradition of excellent optics performance and durability, the CX23 has been designed to be easy to use, with consideration for the series of steps involved in microscope training, from setup through to observation and tidying up afterwards. This facilitates use of the microscopes in educational training at university and other teaching laboratories.

Olympus Corporation Announces Notice Concerning Settlements of Lawsuits for Damages

Olympus Corporation announced that it reached out-of-court settlements, as detailed below, with regard to the civil actions filed by 92 entities in total including foreign institutional investors and pension funds in the Tokyo District Court for ¥36,085,384,346 in damages, as announced in the timely disclosures dated November 13, 2012 ‘Notice Concerning the Filing of Lawsuit against Olympus Corporation’ and dated July 16, 2013 ‘Notice Concerning the Filing of Lawsuit against Olympus Corporation.’ One was filed on June 28, 2012 against the Company to seek compensation for aggregate damages of ¥19,253,038,393 pursuant to Articles 709 and 715 of the Civil Code, Article 350 of the Companies Act and Article 21-2.1 of the Financial Instruments and Exchange Act by 49 entities in total including foreign institutional investors and pension funds, alleging the false statements made by the company in the Annual Securities Reports, Semi- Annual Reports and Quarterly Reports for the fiscal year 2000 through the first quarter of the fiscal year 2011 and the Internal Control Reports for the fiscal years 2008 through 2010 for the purpose of deferring record of losses, as announced in the timely disclosure dated November 8, 2011 ‘Notice Concerning Past Activities Regarding Deferral in Posting of Losses.’ The other was filed on June 27, 2013 against the Company to seek compensation for aggregate damages of ¥16,832,345,953 pursuant to Articles 709 and 715 of the Civil Code, Article 350 of the Companies Act and Article 21-2.1 of the Financial Instruments and Exchange Act by 43 entities in total including foreign institutional investors and pension funds. Note that ¥6 billion of the above ¥17 billion is for the settlement money for the lawsuit, as announced in the timely disclosure dated November 18, 2013 ‘Notice Concerning Settlement of Lawsuit,’ and therefore, the lawsuits subject to the ¥17 billion provisions for losses on lawsuits are now all settled.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OCPNF:US $38.19 USD 0.00

OCPNF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AMETEK Inc $51.71 USD -1.10
CR Bard Inc $171.06 USD +0.19
Smith & Nephew PLC 1,136 GBp -10.00
St Jude Medical Inc $67.76 USD -0.52
Terumo Corp ¥3,145 JPY -65.00
View Industry Companies
 

Industry Analysis

OCPNF

Industry Average

Valuation OCPNF Industry Range
Price/Earnings 38.1x
Price/Sales 2.0x
Price/Book 3.6x
Price/Cash Flow 20.1x
TEV/Sales 1.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OLYMPUS CORP, please visit www.olympus-global.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.